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Abstract
Family history of breast cancer is an established risk factor for breast cancer. In addition, there is evidence that oral
contraceptive use may be associated with a moderate increase in breast cancer risk. The three cohort studies that
have investigated the relationship between oral contraceptive use and breast cancer risk among women with a family
history of breast cancer have yielded mixed results, possibly due to the relatively small sample sizes employed and/or
differences in the selection of covariates for inclusion in multivariate models. Therefore, we examined the associ-
ation between oral contraceptive use and breast cancer risk in a large cohort study in Canada. The cohort consisted
of the 27,318 women in the Canadian National Breast Screening Study who reported a family history of breast
cancer on enrolment into the study. Linkages to national mortality and cancer databases yielded data on deaths and
cancer incidence, with follow-up ending between 1998 and 2000, depending upon the province. During a mean of
16.0 years of follow-up, we observed 1707 incident cases of breast cancer among women with any history of breast
cancer of which 795 cases occurred among women with a mother, sister, and/or daughter with breast cancer. Among
women with any family history of breast cancer, ever use of oral contraceptives was associated with a 12%
reduction in risk of breast cancer (95% confidence interval [CI]=0.73–1.07), and there was an inverse trend with
increasing duration of use of borderline statistical significance (ptrend=0.03). Although we also observed a 25%
lower risk of breast cancer associated with oral contraceptive use of greater than 84 months versus never use among
women with a first degree relative with breast cancer, this finding was not statistically significant (95% CI=0.47–
1.19, ptrend=0.48). Our data raise the possibility that relatively long duration of oral contraceptive use may be
inversely associated with risk among women with a family history of breast cancer.
Introduction
Breast cancer is the most common cause of cancer death
among women worldwide [1]. Having a family history of
breast cancer is an established risk for increasing a
woman’s own risk [1]. Oral contraceptive use has also
been found to be associated with a modest increased risk
of breast cancer [2]. Because women with a family his-
tory of breast and/or ovarian cancer may be counseled
to use oral contraceptives to reduce ovarian cancer risk
[3, 4], the potential association with breast cancer risk in
this population is also of interest, particularly given
evidence that oral contraceptive use may increase breast
cancer risk among women with BRCA1 [5, 6] and
BRCA2 mutations [6].
To date, there appear to have been only three cohort
studies of oral contraceptive use and breast cancer risk
among women with a family history of breast cancer.
Lipnick et al. [7], in analyses of data from the Nurses’
Health Study (71 incident cases), observed no associa-
tion between oral contraceptive use among women with
a family history of breast cancer. Colditz et al. [8]
reanalyzed these data in 1996 (310 incident cases) and
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found a statistically non-significant 2.5-fold increased
risk among current oral contraceptive users with a
family history of breast cancer. In addition, Grabrick
et al. [9] analyzed data from an historical cohort of
women and found that OC use was positively associated
with breast cancer risk among sisters and daughters of
breast cancer cases, but found no association with risk
among granddaughters and nieces of cases. Given the
conflicting results in the existing literature, we examined
the association between oral contraceptive use and
breast cancer risk in a large cohort study, which con-
sisted of 27,323 Canadian women who had a family
history of breast cancer.
Methods
Study population
The design of our study has been described in detail
elsewhere [10]. Briefly, 89,835 women aged 40 to
59 years were recruited into the Canadian National
Breast Screening Study (NBSS) between 1980 and 1985
from the general Canadian population [11].
Questionnaires
At recruitment into the cohort, participants completed
self-administered questionnaires that sought informa-
tion on demographic characteristics, lifestyle factors,
menstrual and reproductive history, and use of oral
contraceptives and replacement estrogens. Specifically,
participants were asked if they had ever used oral con-
traceptives either for birth control or menstrual irregu-
larities. Women who responded ‘yes’ were then queried
as to their duration of use, and if they were no longer
using oral contraceptives, the year in which they stopped
using them. Women were also asked if they had a family
history of breast cancer; those who responded in the
affirmative were then asked to indicate the nature of that
relationship. Women who reported having a mother,
sister, and/or daughter who had breast cancer were
classified as having a first degree relative with breast
cancer. Women who reported having a grandmother or
aunt with breast cancer were classified as having a sec-
ond degree relative.
Ascertainment of incident breast cancer cases and deaths
Incident cases of breast cancer and deaths from all
causes were ascertained respectively by means of com-
puterized record linkages to the Canadian Cancer
Database and to the National Mortality Database, both
of which are maintained by Statistics Canada. The
linkages to the databases yielded data on cancer inci-
dence and mortality to 31 December 2000 for women in
Ontario, 31 December 1998 for women in Quebec, and
31 December 1999 for women in other provinces.
Statistical analysis
Of the 89,835 women recruited into the study, we ex-
cluded women with no family history of breast cancer
(n=62,828) leaving 27,975 women with any family his-
tory of breast cancer (1707 incident cases) amongst
whom 10,914 reported having a first degree relative with
breast cancer (795 incident cases) and 13,155 reported
having a second degree relative with breast cancer (968
incident cases). The remaining 214 subjects were more
distantly related to women with breast cancer.
Cox proportional hazards models (using age as the
time scale) were used to estimate hazard ratios (HR) and
95% confidence intervals (CI) for the association be-
tween oral contraceptive use and breast cancer inci-
dence. For these analyses, cases were considered at risk
from their date of enrollment until the date of diagnosis
of their breast cancer, and non-cases were considered at
risk from their date of enrollment until the termination
of follow-up (the date to which cancer incidence data
were available for women in the corresponding prov-
ince) or death, whichever occurred earlier. Multivariate
models included the variables listed in the footnote of
Table 2. To test for trend we fitted the median value of
each category of duration of oral contraceptive use as an
ordinal variable in the risk models, and evaluated the
statistical significance of the coefficient using the Wald
test [12]. Use of the lifetest procedure in SAS showed
that the proportional hazards assumption was met in
this dataset. All analyses were performed using SAS
version 9 (SAS Institute Cary, NC).
Results
The average duration of follow-up for cohort members
was 16.0 years, corresponding to a total of 448,629
person-years of follow-up for the cohort. The mean
(S.D.) age at diagnosis for the cases was 58.3
(±7.7) years. Overall, 59% of women included in these
analyses reported ever using oral contraceptives, which
is similar to the prevalence of use among women who
reported no family history of breast cancer (58%, not
included in these analyses). Among women with a first
degree relative with breast cancer, 56% reported ever
using oral contraceptives, and 62% of women with a
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second degree relative with breast cancer reported ever
using oral contraceptives (data not shown).
Table 1 shows the demographic characteristics of the
study population by case status at the end of follow-up.
Briefly, cases and controls were broadly similar in all
variables except history of breast disease and parity
(Table 1). Cases were more likely to have a personal
history of breast disease and more likely to be nullipa-
rous than non-cases (Table 1).
Table 2 shows the associations between oral contra-
ceptive use and breast cancer risk among women with a
family history of breast cancer by degree of relatedness.
Among women with any family history of breast cancer,
ever use of oral contraceptives was associated with a
slightly lower risk of breast cancer (HR=0.88, 95%
CI=0.73–1.07) and we observed a statistically sig-
nificant inverse trend with duration of oral contraceptive
use of borderline statistical significance (ptrend=0.03),
after adjustment for potential confounding variables.
We observed similar patterns of association among
women who reported having an aunt and/or grand-
mother with breast cancer, although the findings were
not statistically significant (Table 2). Table 2 also shows
the associations between oral contraceptive use and
breast cancer risk among women with a first degree
relative (mother, sister, and/or daughter) with breast
cancer. In multivariate-adjusted models, we observed no
association between ever use of oral contraceptives and
risk of breast cancer (HR=1.03, 95% CI=0.78–1.38).
Although we observed a 25% lower risk for the highest
level of duration of use compared to never users, this
difference was not statistically significant (95%
CI=0.47–1.19, ptrend=0.48).
Discussion
In the prospective study reported here, there was some
suggestion of an inverse association between duration of
oral contraceptive use and breast cancer risk among
women with any family history of breast cancer. The
association between oral contraceptive use of relatively
long duration and risk among women with a first degree
relative with breast cancer was of similar magnitude to
that observed overall and to that for women with a
second degree relative with breast cancer, although in
neither of these sub-groups were the associated trends
with duration of use statistically significant.
Case-control studies by Ursin et al. [6] and Narod
et al. [5] have examined the association between oral
contraceptive use and breast cancer risk among women
with BRCA1 and/or BRCA2 mutations. While Ursin
et al. observed an increased risk associated with long
term oral contraceptive use (>48 months, ptrend=0.004)
prior to a first full-term pregnancy, this finding was
based on 14 cases only (9 with a BRCA1 mutation and
five with a BRCA2 mutation). Narod et al. [5] observed
a statistically significant 20% increased risk among
BRCA1 mutation carriers (981 cases) who had ever used
oral contraceptives, but noted that this association did
not hold for oral contraceptive use after age 30. Narod
Table 1. Baseline characteristics of the women with any family history of breast cancer by outcome
Non-cases Cases
No. of Individuals 26.268 1.707
Age at baseline in years (SD) 48.5 (5.7) 49.5 (5.6)
Body mass index (SD)a 25.1 (4.7) 25.3 (4.6)
No vigorous physical activity (%) 28.7 31.1
Alcohol consumption (% ever drinker) 26.6 25.0
Smoking history (% ever smoker) 49.3 50.6
Oral contraceptive use (% ever) 59.4 56.4
Mean (SD) duration of oral contraceptive use (months)b 54.2 (51.5) 52.3 (51.0)
HRT (% ever)c 52.8 55.6
History of breast disease (% yes) 17.7 20.9
Age at menarche (%>12 years) 58.5 59.2
Nulliparous (%) 14.9 18.8
Mean (SD) age at first live birth (years)d 24.3 (4.7) 24.8 (4.9)
Postmenopausal at baseline (%) 42.9 45.0
a BMI=Body mass index (kg/m2).
b Duration of oral contraceptive use among ever users.
c HRT=hormone replacement therapy; among postmenopausal women only.
d Among parous women.
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et al. [5] also observed no association between oral
contraceptive use and breast cancer risk among BRCA2
mutation carriers (330 cases). In contrast, Milne et al.
[13], in a multi-center population based case-control
study (1156 incident cases), observed an inverse associ-
ation between oral contraceptive use and risk of early-
onset (before age 40) breast cancer for BRCA1 mutation
carriers, but not for BRCA2 mutation carriers. In
addition, three previous cohort studies (two prospective,
one retrospective) have examined the relationship be-
tween oral contraceptive use and breast cancer risk
among women with a family history of breast cancer.
Our results support the findings of Lipnick et al. [7] who
analyzed data from the Nurses’ Health Study in 1986 (71
incident cases) and observed no association between
ever use of oral contraceptives and age-adjusted breast
cancer risk among women with either a mother or sister
with breast cancer. In a reanalysis of data from the
Nurses’ Health Study in 1996 (310 incident cases),
Colditz et al. [8] observed a 2.5-fold increased risk of
breast cancer among current oral contraceptive users
with any family history of breast cancer (95% CI=0.88–
6.94), after adjustment for age, age at menarche, parity,
menopause and age at menopause, history of benign
breast disease, and use of postmenopausal hormones.
This analysis, however, was based on only four breast
cancer cases among current oral contraceptive users and
was not statistically significant [8]. Unlike these analy-
Table 2. Breast cancer risk and OC use among women with a family history of breast cancer
Cases/Person-years Unadjusted Adjusteda
HR 95% CI HR 95% CI
Women with any family history of breast cancerb,c
Never user 745/182,112 1.00 Referent 1.00 Referent
Ever user 962/266,497 0.97 0.88–1.08 0.88 0.73–1.07
Former 917/255,315 0.97 0.87–1.08 0.88 0.72–1.07
Current 45/10,968 0.99 0.72–1.37 1.01 0.56–1.81
Duration of use
1–12 months 230/54,419 1.10 0.94–1.29 1.05 0.79–1.42
12–36 months 226/60,731 0.99 0.85–1.16 0.94 0.70–1.26
36–84 months 263/80,230 0.90 0.77–1.04 0.85 0.64–1.12
‡84 months 243/71,101 0.93 0.78–1.08 0.74 0.55–0.99
ptrend 0.12 0.03
Women with 1st degree relative with breast cancerd
Never user 362/75,561 1.00 Referent 1.00 Referent
Ever user 433/98,521 1.04 0.89–1.21 1.03 0.78–1.38
Former 413/94,481 1.04 0.89–1.21 1.04 0.78–1.39
Current 20/3,922 1.12 0.70–1.81 1.06 0.43–2.62
Duration of use
1–12 months 100/19,854 1.21 0.96–1.52 1.18 0.75–1.38
12–36 months 107/22,552 1.08 0.86–1.37 1.24 0.82–1.88
36–84 months 120/29,643 0.94 0.76–1.18 1.07 0.72–1.59
‡84 months 106/26,471 0.97 0.78–1.22 0.75 0.47–1.19
ptrend 0.62 0.48
Women with 2nd degree relative with breast cancere
Never user 284/79,596 1.00 Referent 1.00 Referent
Ever user 414/132,202 0.93 0.79–1.10 0.74 0.54–1.00
Former 396/126,653 0.94 0.79–1.10 0.73 0.53–0.99
Current 18/5,487 0.90 0.54–1.50 0.88 0.35–2.18
Duration of use
1–12 months 101/26,738 1.04 0.82–1.33 0.92 0.58–1.44
12–36 months 92/29,706 0.94 0.73–1.20 0.72 0.45–1.17
36–84 months 110/40,237 0.84 0.70–1.06 0.52 0.32–0.84
‡84 months 111/35,504 0.94 0.75–1.18 0.84 0.55–1.27
ptrend 0.24 0.06
a Multivariate models adjusted for age (as time to event variable), alcohol consumption, history of breast disease, age at menarche, parity, age
at first birth, menopausal status, HRT use, BMI, and participation in vigorous physical activity, study center, and randomization group.
b Analysis includes women who reported any family history of breast cancer including, but not limited to, first and second degree relatives.
c Additional adjustment for number of relatives with breast cancer.
d Additional adjustment for number of first degree relatives with breast cancer.
e Additional adjustment for number of second degree relatives with breast cancer.
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ses, which included fewer than 7000 women with a
family history of breast cancer, our study included
approximately 27,000 women with a family history of
breast cancer. More recently, Grabrick et al. [9] ana-
lyzed data from an historical cohort which included
relatives of breast cancer cases (394 first degree relatives/
38 cases and 3002 second degree relatives/115 cases),
and observed a three-fold increased risk of breast cancer
associated with ever use of oral contraceptives among
sisters and daughters of women with breast cancer (95%
CI=1.6–6.7) and no association among nieces and
granddaughters of women with breast cancer (RR=1.2,
95% CI=0.8–2.0) after adjustment for age and birth
cohort. However, this study differed from ours in that
the mean age at breast cancer diagnosis was younger the
mean duration of oral contraceptive use was longer.
The prospective design and the large sample size are
strengths of our study. However, although we adjusted
our estimates for a wide range of potentially con-
founding variables, uncontrolled confounding other
factors cannot be excluded. In addition, family history
of breast cancer was assessed only at baseline and
therefore misclassification due to change in family his-
tory during the follow-up period cannot be ruled out.
Detection bias may have influenced our results if women
with a family history, particularly those with a first de-
gree family history who used oral contraceptives, were
more likely to have had mammograms. Although we did
adjust for randomization group, thus limiting the pos-
sibility of detection bias, we were not able to account for
differences in mammography frequency after the end of
the active follow-up phase of the NBSS and therefore
detection bias cannot be ruled out completely.
Finally, information on BRCA1/BRCA2 mutation
carrier status for the women in this population was not
available. Recent analyses of the association between oral
contraceptive use and breast cancer risk among women
with BRCA1 and BRCA2 mutations have been carried
out by Narod et al. [5] and Milne et al. [13]. Both studies
found no association among women with BRCA2
mutations [5, 13]. The results for women with BRCA1
mutations, however, have been mixed. Narod et al. [5]
observed a positive association between breast cancer and
oral contraceptive use among women with BRCA1
mutations while, in contrast,Milne et al. [13] observed an
inverse association among women with BRCA1 muta-
tions. Additional studies are needed to further examine
any potential association between oral contraceptive use
and breast cancer risk by mutation carrier status, partic-
ularly among with BRCA1 mutations.
In conclusion, our study raises the possibility that
relatively long duration of oral contraceptive use may be
inversely associated with breast cancer risk among
women with a family history of breast cancer. However,
these observations require confirmation in other studies,
particularly those that assess BRCA1/BRCA2 mutation
carrier status.
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